In haemophilia gene therapy trials, the vector‐induced immune response often manifests as an asymptomatic increase in liver transaminases, referred to as transaminitis, with alanine aminotransferase (ALT) levels rising earlier and more significantly than aspartate aminotransferase (AST) levels. The gene discussed is GPT; the disease is hemophilia.